The biotech startup KeyZell has officially announced the upcoming pre-sale offer of its exclusive fungible token useful to receive the service of its Artificial Intelligence system for cancer prevention medicine, and another non-fungible token of the industrial property of this AI.

KeyZell will conduct a Token Generation Event (TGE) through the K2Z Utility Token project, based on the maximum issuance of 2 billion tokens and 20,000 NFT.  Thus, it aims with this TGE to demonstrate the efficacy of a new generation of first-line drugs for the treatment of cancer, as well as to obtain a more advanced version of its AI solution.

The startup has developed OPS (Oncology Precision System), anI-A solution capable of proposing the best combination of cancer treatments customised for each patient, through a Machine Learning system. This innovative solution makes it easier for oncologists to define and select the most appropriate treatment for each patient, taking into account their individual genetic characteristics.

The project consists of the tokenisation of the commerciality of its AI system through the maximum issuance of 2,000 million tokens and 20,000 NFT. Users will get one NFT for every 100,000 tokens. The token will run natively on the Binance Smart Chain blockchain following the BEP-20 standard. Thus, these users will benefit from the ability of this industrial property to generate new tokens and participate in an airdrop.

"The issuance of K2Z aims to radically change the situation in the health sector, eliminating economic barriers to market entry, and to be able to work on the most important purpose, to save lives, and not use it as a mere speculative investment.  We want to bring with the usefulness of this token a diagnostic service of personalised treatment against cancer of precision medicine and that patients can get with the NFT new tokens every year to use them with AI", says José de Corral, CEO of KeyZell.

Token pre-sale phases

The private offer made by KeyZell has vesting the release of the K2Z at a rate of 1/12 per month once the lock-up period has ended, with a total of 200,000 tokens issued. Once this phase has been completed, KeyZell will launch in October the public offering through the issuance of 600,000 tokens in three public phases, and a maximum of 6,000 NFT.

This phase will last approximately one month from the time of its launch, with a starting price of €0.010 for each token and a minimum of €1,000 for subscription limits, and a maximum of €300,000.

"Con K2Z Utility Token we seek to carry out clinical trials (in humans) in its different phases to have a treatment against breast and lung cancer, and subsequently validate the data in PAHO," says José de Corral.

** Investing in crypto assets is not regulated, may not be suitable for retail investors and the entire amount invested may be lost. It is important to read and understand the risks of this investment that are explained in detail in this location.  KeyZell has submitted all the documentation of the project to the National Securities Market Commission (CNMV) to certify compliance with circular 1/2022.

About KeyZhim

KeyZell is formed by a multidisciplinary group of professionals from various fields, researchers from recognised centers of high prestige such as the University of Seville, the University of Malaga or Imperial College London, engineers with management experience in large international projects, and senior professionals from the pharmaceutical, legal and business sectors. The company is also backed by a highly qualified team of advisors, not only in the medical or scientific area but also in intellectual property, legal or strategic issues.

Currently, KeyZell is working on several lines of research, on the one hand, a new first-line treatment against some types of tumors, pending the start of the clinical trial in phase I / IIa, a pre-clinical phase treatment to prevent metastasis. On the other hand, it develops the innovative artificial intelligence system KEYZELL OPS, of which it already has its industrial license, which aims to be the future of precision medicine in oncology, and which starts from the search for patterns and personalised treatments for those cancer patients who do not respond to treatments, offering the most appropriate treatment for cancer,  in the right order and at the most appropriate time according to the characteristics of each patient.

Recently the startup has been awarded the Isaac Peral National Awards for Research, Science, and Innovation granted by the European Association of Economy and Competitiveness (AEDEEC) and has been recognised by the British magazine Health Tech World as one of the 50 best innovative companies in technology in the health sector in 2022.